Of 1463 liver allograft recipients receiving the combination of FK506 and steroids as their primary immunosuppressive regimen, 2 patients developed Kaposi's sarcoma. Although previously described as a complication of organ transplantation, this is the first case report of Kaposi's sarcoma occurring in association with the macrolide immunosuppressive agent FK506. A discussion of the clinical presentation and course of Kaposi's sarcoma in these 2 patients, as well as a review of the past literature on Kaposi's sarcoma in organ transplant recipients, emphasizes the therapeutic difficulties encountered. Kaposi's sarcoma is also compared to lymphoproliferative disorders, another well-recognized complication of immunosuppression, highlighting the differences between these two entities.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3002425 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Regression of Clinically Diagnosed Ocular Kaposi Sarcoma Post-Initiation of Highly Active Antiretroviral Therapy.
Am J Trop Med Hyg
December 2024
Department of Ophthalmology, Faculty of Medical Sciences, The University of the West Indies, St. Michael, Barbados.
Kaposi sarcoma is a low-grade vascular neoplasm linked to the human herpesvirus 8, with the AIDS-associated epidemic variant being the most common and aggressive. Although Kaposi sarcoma more commonly affects the cutaneous tissues, lymph nodes, and visceral organs, it can also be present in ocular and ocular adnexal tissues. We report a case of a 58-year-old Indo-Caribbean woman living with AIDS who presented with a large upper eyelid mass that was clinically diagnosed as Kaposi sarcoma.
View Article and Find Full Text PDFPrevalence of Kaposi sarcoma in the United States: SEER cross-sectional study.
Proc (Bayl Univ Med Cent)
December 2024
Cullen College of Engineering, University of Houston, Houston, Texas, USA.
Primary Kaposi sarcoma (KS) is a rare cancer caused by human herpesvirus-8 that most often affects people with compromised immune systems. Since knowledge of the relationship between disease and sociodemographic factors contributes to the development of precision medicine, we investigated the prevalence of KS within the US population. Using SEER, we found that the Black population had the highest prevalence rate in 2018 compared to other racial groups.
View Article and Find Full Text PDFAbdominal kaposiform hemangioendothelioma presenting as volvulus and recurring intestinal obstruction in a neonate: a case report.
J Med Case Rep
December 2024
Department of Surgery, Aga Khan University, Karachi, Pakistan.
Background: Kaposiform hemangioendothelioma is a rare vascular tumor primarily occurring in infants and children. The most common sites for kaposiform hemangioendothelioma are extremities, with very few cases of abdominal kaposiform hemangioendothelioma reported in neonates. Making a diagnosis of Kaposiform hemangioendothelioma can be challenging when the patient presents with generalized symptoms such as bilious vomiting and constipation that can be attributed to other more common causes of intestinal obstruction.
View Article and Find Full Text PDFHistologic and immunologic factors associated with response to immune checkpoint inhibitors in advanced sarcoma.
Clin Cancer Res
December 2024
Stanford University, Palo Alto, California, United States.
Purpose: To characterize factors associated with response to immune checkpoint inhibitors (ICIs) in advanced sarcoma.
Experimental Design: This is a retrospective study with a cohort of 216 patients with advanced sarcoma treated with ICIs between 2016-2023 at Stanford Health Care. Overall survival (OS), progression free survival (PFS), objective response rates per RECIST criteria (ORR), and reason for ICI discontinuation were analyzed across histologic subtypes, ICI regimens, tumor mutational burden (TMB), and PD-L1 expression.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!